Press release
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GSK
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline
DelveInsight reports that over 25 major companies are actively engaged in developing more than 30 treatment therapies for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC).
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Overview:
Lung cancer remains one of the top causes of cancer-related deaths globally and is often associated with a poor prognosis. However, the advent of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the treatment approach for patients with non-small cell lung cancer (NSCLC). Blocking the PD-1 receptor and its ligand PD-L1 has shown significant therapeutic benefits and improved survival outcomes in both preclinical and clinical settings for patients with locally advanced or metastatic NSCLC.
PD-1 is a Type I transmembrane protein found on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells (DCs). Its two ligands, PD-L1 and PD-L2, are also Type I transmembrane proteins but differ in their expression patterns. PD-L1 is present on T cells, B cells, DCs, macrophages, various non-hematopoietic cells, and tumor cells. Structurally, PD-1 and its ligands include a signal sequence, an immunoglobulin (Ig) domain, transmembrane domains, and a short cytoplasmic tail.
When PD-1 binds to PD-L1 or PD-L2, it becomes phosphorylated at two intracellular tyrosine residues. This triggers the recruitment of phosphatases SHP-1 and SHP-2, which bind to the ITIM and ITSM motifs on PD-1, leading to the suppression of antigen receptor signaling. The PD-1/ligand interaction inhibits effector T-cell activity, whereas the binding of B7-1/B7-2 with CD28 supports T-cell proliferation.
Request for a detailed insights report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutics Market.
Key Takeaways from the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Report
*
DelveInsight's PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report highlights a dynamic field with over 25 companies actively developing more than 30 therapies for PD-1+ NSCLC treatment.
*
Leading companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others are investigating new drug candidates to enhance the treatment options for this disease.
*
Notable pipeline therapies in various stages of development include Zimberelimab, PM8002, RPH075, among others.
*
In August 2025, the FDA approved AstraZeneca's durvalumab for treating adult NSCLC patients post-surgery, broadening its application beyond advanced cases where surgery is not feasible. Earlier, in January 2023, the FDA approved pembrolizumab as an adjuvant therapy after surgical resection and platinum-based chemotherapy for patients with stage IB (T2a greater than or equal to 4 cm), II, or IIIA NSCLC.
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) market.
Download our free sample page report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Emerging Drugs
*
Zimberelimab: Arcus Biosciences
*
PM8002: Biotheus
*
RPH075: R-Pharm
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Companies
Over 25 leading companies are actively working on developing therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Notably, Arcus Biosciences is among those with drug candidates currently in the most advanced stage of development, specifically Phase III.
DelveInsight's report covers around 30+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapies and Key Companies: PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials and advancements [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Therapeutic Assessment
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Product Type
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) By Stage
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Route of Administration
- PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Molecule Type
Download PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Sample report to know in detail about the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment market @ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutic Assessment [https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Current Treatment Patterns
4. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Late-Stage Products (Phase-III)
7. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Discontinued Products
13. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Product Profiles
14. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Companies
15. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Products
16. Dormant and Discontinued Products
17. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Unmet Needs
18. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Future Perspectives
19. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Reports Offerings [https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-pd1-nsclc-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-arcus-biosciences-akeso-biopharma-biotheus-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GSK here
News-ID: 4142787 • Views: …
More Releases from ABNewswire
Canadian Stocks to Watch for 2026: WRLG - PNPN - DOSE - AMY - Also Trading in th …
West Red Lake Gold Mines Ltd. (TSXV: WRLG | OTCQX: WRLGF) declared commercial production at its 100%-owned Madsen Gold Mine in Ontario's Red Lake District effective January 1, 2026, marking a key milestone just seven months after completing a bulk sample. In December 2025, the mill averaged 689 tpd (86% of permitted capacity) with 94.6% recoveries, producing 3,215 oz of gold; Q4 2025 output totaled 7,200 oz poured, sold at…
Aether Holdings, Inc. (NASDAQ: ATHR): Turning Investor Attention Into Actionable …
Retail participation is quietly rebuilding momentum in early 2026. Trading activity across equities and digital assets is increasing, speculative interest is returning, and investor attention is spreading across more platforms, newsletters, and social channels than ever before. Yet while participation is rising, signal quality remains uneven. Investors face more data, more commentary, and more noise, but not necessarily better insight.
That gap between participation and actionable intelligence is becoming increasingly visible.…
Riverhouse Hospitality Celebrates Milestones, Maritime Legacy, and a Continued C …
Riverhouse Hospitality, one of Connecticut's premier hospitality and event groups, is celebrating a series of major milestones that underscore its long-standing commitment to quality, craftsmanship, and the preservation of historic venues across the state.
The company's latest expansion, Riverhouse Cruises, marks a new chapter in Riverhouse Hospitality's mission to create unforgettable experiences rooted in Connecticut's history and natural beauty. Anchored by the iconic Lady Kate, Riverhouse Cruises continues a proud maritime…
SendTurtle Introduces eSignature Upgrade with Cleaner Interface and Dedicated Ap …
SendTurtle launches an upgraded eSignature experience with a cleaner UI and a dedicated app section, built directly from user feedback to streamline signing workflows.
Arlington, VA - January 20, 2026 - SendTurtle, the smart eSignature and secure deal productivity platform, announced today a major upgrade to its eSignature experience. The update introduces a cleaner, more intuitive user interface and places eSignature into its own dedicated section of the SendTurtle app, making…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
